5.5 C

European countries stop using AstraZeneca personnel due to concerns about blood tissue

Must read

The suspension of various batches by Italy was related to a man in Sicily who died after receiving his shot. It is unclear whether a thrombus is involved.

In Denmark, which has a population of about six million, more than 142,000 people have been vaccinated with the AstraZeneca vaccine.

The Minister of Health of Denmark Magnus Heunike, says on Twitter that “at present it is impossible to conclude whether there is a connection.” He added. “We acted quickly, it needs to be studied carefully.”

Denmark has already reduced its goal of partially ending its vaccine campaign, in part due to delays in deliveries. The security breach will delay it further.

The AstraZeneca vaccine was passed last year when it was being tested in clinical trials over possible safety issues. Two British vaccinated volunteers developed neurological symptoms similar to transverse myelitis, an inflammatory syndrome of the spinal cord often caused by viral infections.

These concerns temporarily halted global vaccine trials, but investigations eventually found no evidence linking the symptoms to the vaccine. It was later revealed that one of the infected participants had an undiagnosed case of multiple sclerosis.

More than 70 countries have since approved the vaccine, with the exception of the United States, where regulators are awaiting data on major clinical trials in the coming weeks. The decision of the Food and Drug Administration to approve the AstraZeneca vaccine will probably take more than a month.

The most comprehensive data on vaccine safety in the real world come from Britain, which injected 9.7 million doses last month. British Drug Regulatory և Health Products Regulatory Agency says:

Rebecca Robbins Reported from Bellingham, Washington և Thomas Erdbrink From Amsterdam. Ason Eason from Horowitz և: Emma Bubola invested in Italy Benjamin Mueller From London և Denise Grady from New York.

More articles


Please enter your comment!
Please enter your name here

Latest article